Core Insights - The session is part of Citi's 2026 Virtual Oncology Leadership Summit, featuring discussions with various companies in the oncology sector [1][2] - IDEAYA's senior management team, including CFOs Josh Bleharski and Michael White, and CMO Darrin Beaupre, is highlighted for their participation in the summit [2] Company Overview - IDEAYA is represented by key executives who are available for questions from the audience, indicating an open communication approach [2] - The summit includes a variety of companies, suggesting a diverse representation within the oncology industry [1]

Group 1 - Telstra Group reported a 9.4% increase in half-year profit, attributed to steady contributions from its mobile business and cost-cutting initiatives [1] - The profit attributable for the six months ended December 31 was A$1.12 billion (approximately $788.03 million), compared to A$1.03 billion in the previous year [1]

Summary of IDEAYA Biosciences Conference Call Company Overview - **Company**: IDEAYA Biosciences (NasdaqGS:IDYA) - **Industry**: Clinical-stage precision medicine oncology - **Key Programs**: Nine clinical programs, with a focus on uveal melanoma and other oncology indications Key Points and Arguments Upcoming Catalysts - **Darovasertib**: Lead molecule for uveal melanoma, with an upcoming top-line data release for the combination with crizotinib in metastatic uveal melanoma expected by the end of March 2026. The company has triggered the required 130 events for analysis [2][5] - **Neoadjuvant and Adjuvant Studies**: Enrollment in a neoadjuvant study is ongoing, with plans to begin an adjuvant study in Q2 2026 [3][4] Clinical Data Expectations - **Control Arm Expectations**: The control arm is expected to show a median progression-free survival (PFS) of 2-3 months and overall survival (OS) of about 13 months based on historical data [9][10] - **Darovasertib and Crizotinib Combination**: Previous data indicated a median PFS of about 7 months and OS of 21 months, significantly better than standard therapies [10][12] - **Response Rates**: Standard therapies show a response rate of around 10%, while the combination therapy has shown a response rate exceeding 30% [10] Study Design and Patient Demographics - The study focuses on HLA-A2 negative patients with metastatic uveal melanoma, comparing the combination therapy to standard care, which varies by region [8][9] - The study design includes frequent patient scans every six weeks, which may lead to earlier detection of progression compared to traditional three-month scans [15] Regulatory and Filing Timelines - **FDA Filing**: The company anticipates a six-month timeline to file for accelerated approval post-data release, with a review period of at least six months [30] - **HLA-A2 Positive Group**: Data from HLA-A2 positive patients will be presented in two chapters, with the first chapter expected to show early efficacy data [31][32] Other Pipeline Developments - **DLL3 TOPO1 ADC**: Currently in phase I studies, with initial data expected by the end of 2026. The U.S. study has launched, and early safety data is anticipated [47][48] - **MTAP Inhibitor IDE397**: Ongoing studies in combination with Trodelvy for MTAP-deleted urothelial cancer, with promising early data [59][60] - **Combination Strategies**: The company is exploring various combination therapies, including those targeting PRMT5 and CDKN2A, to enhance treatment efficacy in MTAP-deficient tumors [66][68] Market Position and Future Outlook - IDEAYA aims to set a new standard for uveal melanoma treatment, addressing a significant unmet medical need with limited existing therapies [22][14] - The company has a strong cash position of approximately $1.05 billion, providing a runway into 2030, positioning it well for upcoming clinical milestones [5] Additional Important Information - The company emphasizes the importance of data integrity and the potential for positive outcomes based on historical performance metrics [12][26] - Discussions with the FDA regarding potential label expansions and real-world data integration are ongoing, particularly for HLA-A2 positive patients [33] This summary encapsulates the key points discussed during the conference call, highlighting IDEAYA Biosciences' strategic focus on advancing its oncology pipeline and addressing critical patient needs in uveal melanoma and other cancer indications.

Clinical Development - The company has a pipeline of nine potential first-in-class product candidates across four clinical focus areas, including Darovasertib for Uveal Melanoma and ADC and DNA Damage Response (DDR) combinations [22]. - Darovasertib is being evaluated in a Phase 2/3 trial (OptimUM-02) for first-line metastatic Uveal Melanoma, with full enrollment of 437 patients completed in December 2025, and topline data expected in Q1 2026 [26]. - In the Phase 2 trial (OptimUM-01), darovasertib combined with crizotinib showed a confirmed objective response rate (ORR) of 34% and a disease control rate (DCR) of 90% among 41 efficacy-evaluable patients [28]. - The company plans to initiate a global Phase 3 trial (OptimUM-11) in the adjuvant setting of primary Uveal Melanoma in H1 2026, enrolling approximately 450 patients [32]. - IDE849, a DLL3 TOP1 ADC, is being evaluated in a Phase 1 clinical trial in China, with positive initial data presented from 100 patients, including 87 refractory SCLC patients [36]. - IDE397 is being evaluated in a Phase 1/2 trial in combination with Trodelvy for MTAP-deleted urothelial cancer, with initial data showing manageable safety and no serious adverse events [47][50]. - The company plans to initiate a Phase 1 clinical trial for IDE034, a B7H3/PTK7 bispecific ADC, in the first quarter of 2026, following FDA IND clearance [40][43]. - The company is targeting to initiate a Phase 1 clinical combination trial with IDE161 and IDE849 in the second quarter of 2026 [42]. - IDE574 received FDA IND clearance and is expected to begin a Phase 1 trial in the first quarter of 2026, with plans for combination trials with IDE397 [55]. - FDA granted IND clearance for IDE275, targeting Phase 1 trial in Q1 2026 for breast, lung, prostate, and colorectal cancers [56]. - The company achieved the first dosing of the first patient in the Phase 1 clinical trial for IDE849, triggering a $2 million milestone payment to Hengrui Pharma [127]. Regulatory Designations and Approvals - The FDA granted Breakthrough Therapy designation for darovasertib as a neoadjuvant treatment for primary Uveal Melanoma in March 2025, expediting its development and regulatory review [33]. - The FDA granted fast track designation to darovasertib in combination with crizotinib for the treatment of adult patients with mUM in November 2022 [164]. - In September 2023, the FDA granted two fast track designations to IDE161 for specific ovarian and breast cancer indications [164]. - The FDA may require Phase 4 clinical trials post-approval to further assess a drug's safety and effectiveness, which could impact the commercial value of the product [151]. - The FDA may issue a Complete Response Letter detailing deficiencies in an NDA, requiring resubmission to address these issues [150]. - The FDA requires substantial time and financial resources for drug regulatory approvals, with potential sanctions for non-compliance, including product recalls and fines [137]. - The NDA submission process includes a preliminary review by the FDA within the first 60 days, with a goal to review and act on applications within ten months for standard review and six months for priority review [148]. - Orphan drug designation is granted for drugs intended to treat rare diseases affecting fewer than 200,000 individuals in the U.S., providing financial incentives such as tax credits and user-fee waivers [154]. Market and Commercialization Strategy - The company plans to build its own sales force for commercialization in the U.S. and potentially Europe, supported by effective marketing and sales management [130]. - The company retains commercialization rights for darovasertib in the U.S. and worldwide rights for several other product candidates, indicating a focus on expanding its commercial capabilities [129]. - The company is targeting to nominate a development candidate for a novel program targeting MTAP and CDKN2A by the first half of 2026 [67]. - The company plans to evaluate future strategic opportunities to accelerate development timelines and maximize the commercial potential of its product candidates [91]. - The company has established collaborations with Pfizer and Gilead for clinical development of darovasertib and IDE397, respectively [67]. - The company has exclusive commercial rights worldwide for IDE397 and IDE161, and all commercial rights within the U.S. for darovasertib [85]. Financial Agreements and Partnerships - An exclusive license agreement with Servier was established in August 2025, providing an upfront payment of $210 million and potential milestone payments of up to $320 million [30]. - An upfront payment of $210 million was received from Servier for the exclusive license agreement to develop darovasertib outside the U.S. [67]. - The Hengrui Pharma License Agreement includes upfront and milestone payments totaling $1.045 billion, with a $75 million upfront fee and up to $200 million in development and regulatory milestone payments [126]. - The company paid Novartis an upfront payment of $2.5 million and issued 263,615 shares of Series B redeemable convertible preferred stock, with potential milestone payments of up to $29 million based on clinical and commercial milestones [104]. - The company entered into a collaboration with Gilead for IDE397, with Gilead providing drug supply and the company sponsoring a Phase 1 clinical trial, sharing oversight responsibilities [107]. Intellectual Property and Patent Portfolio - The company has a patent portfolio comprising approximately 71 distinct patent families, including 21 issued U.S. patents and 65 issued foreign patents, with expiration dates ranging from 2035 to 2046 [79]. - The PKC program, including darovasertib, has approximately seven issued U.S. patents and 34 issued foreign patents, with expiration dates between 2035 and 2045 [80]. - The MAT2A program, including IDE397, consists of five issued U.S. patents and nine issued foreign patents, with expiration dates between 2039 and 2045 [81]. - The PARG program, including IDE161, has four issued U.S. patents and 17 issued foreign patents, with expiration dates between 2035 and 2044 [82]. Market Environment and Regulatory Challenges - The U.S. annual incidence of MTAP-deleted tumors is estimated at approximately 62,000 patients across priority tumor types, highlighting a significant unmet medical need [53]. - The FDA may withdraw approval if compliance with regulatory standards is not maintained or if problems occur after the product reaches the market [166]. - The FDA may deny PMA approval based on deficiencies in the application, requiring additional clinical trials that can delay approval [180]. - The FDA requires that a companion diagnostic be approved contemporaneously with the therapeutic product if it is essential for safe and effective use [175]. - The FDA may impose post-approval conditions necessary to ensure the safety and effectiveness of a device, including restrictions on labeling and promotion [179]. - The FDA conducts inspections of manufacturing facilities to ensure compliance with cGMP requirements before approving an NDA [149]. Economic and Legislative Factors - The Affordable Care Act (ACA) increased Medicaid rebates from 15.1% to 23.1%, affecting revenue for pharmaceutical manufacturers [208]. - The Inflation Reduction Act of 2022 mandates price negotiations for certain drugs under Medicare, with penalties for price increases exceeding inflation, impacting future revenue forecasts [211]. - The One Big Beautiful Bill Act, enacted in July 2025, is expected to reduce Medicaid enrollment and services, adversely affecting sales of commercialized products [213]. - The U.S. government and states are increasingly implementing regulations to control pharmaceutical pricing, which may limit sales and reimbursement for products [215]. - The EU's Regulation No 2021/2282 on Health Technology Assessment (HTA) aims to enhance cooperation in assessing health technologies, potentially affecting product pricing and reimbursement decisions [217]. - Pharmaceutical companies face penalties for non-compliance with healthcare regulations, including civil and criminal penalties, which could impact operational capabilities [218]. - Data privacy laws are evolving, potentially complicating compliance and leading to significant penalties for violations, affecting operational processes [219]. - Coverage and reimbursement decisions by third-party payors are increasingly restrictive, which could adversely affect product sales and market demand [220].

Financial Performance - As of December 31, 2025, IDEAYA had approximately $1.05 billion in cash, cash equivalents, and marketable securities, down from $1.08 billion as of December 31, 2024, primarily due to net cash used in operations[12]. - The net loss for Q4 2025 was $83.3 million, compared to a net loss of $130.3 million for Q4 2024, with total stock compensation expense increasing to $11.8 million from $9.5 million[18]. - For the full year 2025, the net loss was $113.7 million, significantly reduced from a net loss of $274.5 million in 2024[19]. - Cash and cash equivalents and short-term and long-term marketable securities decreased to $1,049.685 million from $1,082.151 million[28]. - Total assets decreased to $1,109.324 million from $1,124.091 million[28]. - Total liabilities increased to $86.390 million from $64.944 million[28]. Revenue and Expenses - Collaboration revenue for Q4 2025 was $10.9 million, an increase from $7.0 million in Q4 2024, with a remaining balance of $161.8 million related to clinical trial cost reimbursements under the license agreement[13]. - Research and development expenses for Q4 2025 totaled $86.6 million, a decrease from $140.2 million in Q4 2024, driven by a prior year's upfront payment offset by higher clinical trial expenses[16]. - General and administrative expenses for Q4 2025 were $18.8 million, up from $11.0 million in Q4 2024, mainly due to increased personnel-related expenses and consulting fees[17]. Clinical Trials and Developments - IDEAYA completed full enrollment of 437 patients in the OptimUM-02 trial, with topline results expected by the last week of March 2026[5]. - The company anticipates initiating three randomized Phase 3 trials for darovasertib in uveal melanoma by H1 2026, including neoadjuvant and adjuvant settings[9]. - IDEAYA received IND clearance for IDE034 in Q4 2025 and plans to initiate a Phase 1 trial in Q1 2026, with a $5 million milestone payment triggered upon dosing the first patient[11]. - The company is targeting to provide preliminary clinical data from the IDE849 Phase 1 trial by the end of 2026 and initiate a registrational study in the second line setting for small cell lung cancer[8].

Core Insights - IDEAYA Biosciences reported strong clinical execution and pipeline expansion in Q4 and full year 2025, with a focus on advancing its oncology programs and commercial readiness activities [1] Financial Results - As of December 31, 2025, IDEAYA had approximately $1.05 billion in cash, cash equivalents, and marketable securities, a decrease from $1.08 billion in 2024, primarily due to net cash used in operations [2] - Collaboration revenue for Q4 2025 was $10.9 million, up from $7.0 million in Q4 2024, driven by research and development services under the Servier exclusive license agreement [2] - R&D expenses for Q4 2025 totaled $86.6 million, down from $140.2 million in Q4 2024, mainly due to a prior year's upfront payment under a license agreement [2] - G&A expenses for Q4 2025 were $18.8 million, an increase from $11.0 million in Q4 2024, attributed to higher personnel and consulting costs [2] - The net loss for Q4 2025 was $83.3 million, compared to a net loss of $130.3 million in Q4 2024 [2] - For the full year 2025, the net loss was $113.7 million, significantly reduced from $274.5 million in 2024 [2] Clinical Developments - IDEAYA is advancing darovasertib in uveal melanoma, with topline results from the OptimUM-02 trial expected by the end of March 2026, which may enable accelerated approval in the U.S. [1] - The company plans to initiate three Phase 3 registrational trials for darovasertib in uveal melanoma by H1 2026 [1] - IDEAYA has received IND clearance for IDE034, a bispecific ADC, and plans to initiate a Phase 1 trial in Q1 2026 [1] - The company is also targeting the initiation of several other clinical trials, including IDE574 and IDE892, in 2026 [1] Corporate Updates - In December 2025, GlaxoSmithKline notified IDEAYA of its intention to terminate a collaboration agreement, leading to the transfer of certain clinical programs back to IDEAYA [1] - The company is actively preparing for the commercial launch of darovasertib in the U.S. and globally [1]

Core Insights - IDEAYA Biosciences, Inc. is a precision medicine oncology company focused on developing targeted therapeutics for specific patient populations using molecular diagnostics [1] - The company has promising product candidates, including IDE397 and IDE196, currently in various stages of clinical trials, alongside a strong preclinical pipeline targeting synthetic lethality programs [1] Price Target Trends - The consensus price target for IDEAYA Biosciences has fluctuated, decreasing from an average of $54.67 a quarter ago to $45 in the past month, which is similar to the target from a year ago at $44 [2] - Analysts from Robert W. Baird have set a price target of $18, reflecting the potential of the company's extensive portfolio and near-term catalysts [5] Lead Asset and Revenue Potential - The lead asset, darovasertib, is aimed at treating uveal melanoma and has shown promising results in Phase 2 trials, with potential peak revenue exceeding $500 million [3] - The success of darovasertib could significantly impact the company's financial performance and stock valuation [3] Strategic Partnerships - IDEAYA has established strong partnerships, including one with Servier and collaborations with major pharmaceutical companies like GlaxoSmithKline plc, which are crucial for accelerating drug development [4] - These partnerships may influence analyst sentiment and price targets moving forward [4]

Group 1 - IDEAYA Biosciences, Inc. is participating in two upcoming investor relations events, including Citi's 2026 Virtual Oncology Leadership Summit on February 18, 2026, and a Virtual Fireside Chat on February 23, 2026 [1] - The company focuses on precision medicine in oncology, aiming to discover and develop targeted therapeutics for cancer treatment [2] - IDEAYA has a robust pipeline of product candidates, particularly in synthetic lethality and antibody-drug conjugates (ADCs), targeting molecularly defined solid tumor indications [2] Group 2 - The company integrates expertise in small-molecule drug discovery, structural biology, and bioinformatics to develop tailored therapies aligned with genetic disease drivers [2] - IDEAYA's mission is to create the next wave of precision oncology therapies that are more selective, effective, and personalized, with the goal of improving clinical outcomes for cancer patients [2]

Company Overview - IDEAYA was founded 10 years ago and has established strategic guideposts including first-in-class targets, predictive biomarkers, rational combinations, and early-stage disease focus areas [3] Clinical Pipeline - The company has four clinical pipeline focus areas, with darovasertib being a key program currently in a registrational study, with top-line results expected this quarter for potential accelerated approval filing in the United States [4] - Darovasertib is considered a unique molecule with the potential to define its indication in uveal melanoma across neoadjuvant, adjuvant, and metastatic settings [4] Research Focus - IDEAYA is also focusing on antibody-drug conjugates (ADCs) and DNA damage repair as part of its research and development strategy [5]

Summary of IDEAYA Biosciences FY Conference Call Company Overview - **Company**: IDEAYA Biosciences (NasdaqGS:IDYA) - **Event**: 44th Annual J.P. Morgan Healthcare Conference - **Date**: January 12, 2026 - **CEO**: Yujiro Hata Key Focus Areas 1. **Darovasertib**: - Currently in a registrational study with top-line results expected this quarter for potential accelerated approval in the U.S. [2][8] - Targets uveal melanoma, a rare and aggressive cancer with a poor prognosis (5-year survival rate of 15%-20%) [6][7] - Reported an overall response rate of approximately 35% and a median duration of response of nine months [7] - Progression-free survival (PFS) reported at seven months, with overall survival (OS) over 21 months [7] - Received Breakthrough Therapy Designation from the FDA for the neoadjuvant setting [9] 2. **Antibody-Drug Conjugates (ADCs)**: - Focus on DNA damage repair and enhancing durability of ADCs [11][12] - DLL3 TOPO-ADC program (ID849) aims to address unmet needs in small cell lung cancer, with a confirmed response rate of approximately 70% in second-line settings [15][16] - Plans to initiate a registrational study for ID849 targeting monotherapy accelerated approval [17] 3. **MTAP Deletion**: - Represents a significant opportunity as it is co-deleted with CDKN2A in various cancers, including lung and pancreatic cancers [19][20] - No FDA-approved therapies currently exist for patients with MTAP deletion [20] - Response rates of approximately 40% reported in ongoing studies, with a focus on non-small cell lung cancer [21][22] 4. **KAT6/7 Inhibitors**: - New dual KAT6/7 inhibitor (ID574) has entered phase one trials, targeting tumor heterogeneity [24] - Expected to address significant patient populations in breast cancer, prostate cancer, and colorectal cancer [24] Clinical Development and Strategy - IDEAYA has a pipeline of nine clinical stage molecules, focusing on precision medicine in oncology [5] - Emphasis on combination therapies to enhance treatment efficacy and durability [29] - Plans to complete enrollment for the neoadjuvant study by the first half of 2027 [11] Market Insights - IDEAYA aims to learn from the Kimmtrak launch in the uveal melanoma market to enhance its market entry strategy for darovasertib [28] - The company is focused on addressing challenges in community access and market penetration [28] Financial and Operational Highlights - IDEAYA is positioned for potential accelerated approval filings and is investing in future growth areas, including TOPO-ADCs and MTAP deletion biology [25] Additional Considerations - The company is exploring the safety and efficacy of various combinations, including the potential for reduced doses to optimize therapeutic windows [40][41] - The focus on systemic therapies versus dual payload approaches highlights a strategic differentiation in their clinical development [42] This summary encapsulates the key points discussed during the conference call, highlighting IDEAYA's strategic focus, clinical developments, and market positioning.